logo
Share SHARE
FONT-SIZE Plus   Neg

RyMed Tech. Wins Patent Infringement Case Against ICU Medical - Quick Facts

A federal jury has found in favor of RyMed Technologies and against ICU Medical (ICUI) in a closely-watched patent infringement case, and ruled that RyMed's InVision-Plus with Neutral AdvantageTM technology products do not infringe on a patent held by ICU Medical.

Dana Wm. Ryan, President, CEO and Chairman of the Board of RyMed said the unanimous ruling by an eight-person jury means that ICU Medical can no longer make any claim that RyMed's products literally infringe on an in-force ICU Medical patent.

Commention on the jury's decision, Ryan continued, " It reinforces our ability to continue providing all of RyMed's innovative technology to the market. In addition to providing a significant boost to our future business prospects, it also affirms our ongoing efforts to bring clinicians and patients the very best in IV catheter safety technology."

The jury decision was announced Wednesday, May 9th in a case heard before Judge Leonard P. Stark, in the United States District Court for the District of Delaware.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Netflix Inc. and movie studio Disney are finally taking their deal that was announced in 2012 to the next level. The online movie rental service will become the exclusive U.S. pay-TV home of the latest films from Disney, Marvel, Lucasfilm and Pixar. Abercrombie & Fitch Co. (ANF) reported a GAAP net loss attributable to company of $39.6 million for the first quarter ended April 30, 2016 compared to a loss of $63.2 million, last year. Excluding certain items last year, net loss attributable to Abercrombie & Fitch Co. increased $2.4 million. Net... Dollar General Corp. (DG) reported first-quarter net income of $295 million, or $1.03 per share compared to $253 million, or $0.84 per share, a year ago. On average, 25 analysts polled by Thomson Reuters expected the company to report profit per share of $0.95 for the quarter. Analysts' estimates typically...
comments powered by Disqus
Follow RTT